Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial

BACKGROUND: The ability of a genetic risk score to predict risk in established cardiovascular disease and identify individuals who derive greater benefit from PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition has not been established. METHODS: We studied 14 298 patients with atheroscl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Circulation
Main Authors: Marston, Nicholas A., Kamanu, Frederick K., Nordio, Francesco, Gurmu, Yared, Roselli, Carolina, Sever, Peter S., Pedersen, Terje R., Keech, Anthony C., Wang, Huei, Pineda, Armando Lira, Giugliano, Robert P., Lubitz, Steven A., Ellinor, Patrick T., Sabatine, Marc S., Ruff, Christian T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8058781/
https://ncbi.nlm.nih.gov/pubmed/31707849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.043805
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados